Gastric Cancer Diagnostics Market Size, Share & Growth Outlook 2032

The Gastric Cancer Diagnostics Market size was valued at USD 1.16 billion in 2024 and is expected to reach USD 2.05 billion by 2032, growing at a CAGR of 7.36% over the forecast period of 2025-2032.

The global Gastric Cancer Diagnostics Market is witnessing sustained growth as healthcare systems emphasize early detection and precision oncology. Rising prevalence of gastric cancer, particularly in aging populations and high-risk regions, has increased reliance on endoscopy, imaging, histopathology, and molecular diagnostics. Continuous improvements in diagnostic accuracy and workflow efficiency are strengthening clinical outcomes and supporting long-term market expansion.

Growing awareness regarding Helicobacter pylori infection, dietary risks, and obesity has further accelerated screening programs worldwide. Governments and private stakeholders are investing in advanced diagnostic technologies, including AI-enabled imaging and non-invasive biomarker tests, to reduce mortality through earlier diagnosis and treatment initiation.

Get free Sample Report@ https://www.snsinsider.com/sample-request/8017

One of the key drivers shaping the market is the rising incidence of gastric cancer globally. Increasing patient volumes require timely and accurate diagnostic solutions, boosting demand for endoscopic procedures, biopsy-based testing, and molecular assays. In February 2025, Japan reported a screening rate of 58%, supported by AI-assisted endoscopy and nationwide awareness initiatives, significantly strengthening diagnostic adoption and market momentum.

Despite strong growth prospects, limited user adaptability and infrastructure gaps remain critical restraints. In low-income and rural regions, shortages of diagnostic facilities, trained professionals, and funding restrict early detection. According to a May 2025 WHO report, over 70% of cancer-related deaths in low-income countries are linked to limited diagnostic access, highlighting persistent disparities that constrain overall market growth.

From a segmentation perspective, reagents and consumables dominated the market in 2024, accounting for 61.30% share. Their recurring use across biopsy, PCR, immunohistochemistry, and liquid biopsy procedures ensures consistent demand. Cost efficiency and ease of integration into existing platforms further reinforce this segment’s leadership, particularly as testing volumes increase globally.

By disease type, adenocarcinoma represented the largest and fastest-growing segment, holding 86.56% market share in 2024 and registering a CAGR of 7.53%. High prevalence, especially across East Asia, and rising screening initiatives have driven demand for HER2, MSI, and biopsy-based diagnostics, significantly contributing to market revenues.

Hospitals emerged as the leading end-user segment with 64.32% share, supported by comprehensive diagnostic infrastructure and experienced clinical teams. Meanwhile, diagnostic laboratories are the fastest-growing end users, driven by automation, high-throughput testing capabilities, and increasing outsourcing of specialized molecular diagnostics.

Regionally, North America dominated the market in 2024 with 44.90% revenue share, supported by advanced healthcare infrastructure, reimbursement coverage, and rapid adoption of AI-based and molecular diagnostics. Europe follows closely, benefiting from government-backed screening programs and strong research ecosystems. Asia Pacific is projected to grow at the fastest CAGR of 8.00%, fueled by high disease prevalence, national screening initiatives, and expanding healthcare access in emerging economies.

Leading companies operating in the market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Illumina, Inc., Agilent Technologies, Inc., GE HealthCare Technologies Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., and Canon Medical Systems Corporation. Recent developments, such as AI-powered oncology software launches and regulatory approvals for HER2 testing solutions, continue to enhance diagnostic precision and efficiency.

Buy Full Report Now: https://www.snsinsider.com/checkout/8017

FAQ

Q1. What is driving growth in the gastric cancer diagnostics market?

Rising gastric cancer incidence, early screening initiatives, and technological advancements are primary growth drivers.

Q2. Which product segment leads the market?

Reagents and consumables lead due to their recurring use across all diagnostic procedures.

Q3. Which region dominates the market?

North America holds the largest revenue share, supported by advanced healthcare systems.

Q4. What is the fastest-growing region?

Asia Pacific is the fastest-growing region with an expected CAGR of 8.00%.

Q5. Who are the key players in this market?

Major players include Roche, Abbott, Thermo Fisher Scientific, Siemens Healthineers, and Illumina.

Other Trending Reports

Medical X-ray Market

Epilepsy Device Market

DNA Sequencing Market

Non-Invasive Fat Reduction Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Rohan Jadhav - Principal Consultant

Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Email: info@snsinsider.com